316 related articles for article (PubMed ID: 21080918)
1. The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
Rudner J; Ruiner CE; Handrick R; Eibl HJ; Belka C; Jendrossek V
Radiat Oncol; 2010 Nov; 5():108. PubMed ID: 21080918
[TBL] [Abstract][Full Text] [Related]
2. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
3. The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model.
Awde AR; Boisgard R; Thézé B; Dubois A; Zheng J; Dollé F; Jacobs AH; Tavitian B; Winkeler A
J Nucl Med; 2013 Dec; 54(12):2125-31. PubMed ID: 24212976
[TBL] [Abstract][Full Text] [Related]
4. ABT-737 and erufosine combination against castration-resistant prostate cancer: a promising but cell-type specific response associated with the modulation of anti-apoptotic signaling.
Avsar Abdik E; Kaleagasioglu F; Abdik H; Sahin F; Berger MR
Anticancer Drugs; 2019 Apr; 30(4):383-393. PubMed ID: 30557204
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic effects of erufosine on small cell and non-small cell lung cancer cells through induction of apoptosis and cell cycle arrest.
Abdik H
Mol Biol Rep; 2022 Apr; 49(4):2963-2971. PubMed ID: 35015224
[TBL] [Abstract][Full Text] [Related]
6. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.
Fiegl M; Lindner LH; Juergens M; Eibl H; Hiddemann W; Braess J
Cancer Chemother Pharmacol; 2008 Jul; 62(2):321-9. PubMed ID: 17922125
[TBL] [Abstract][Full Text] [Related]
7. Dual Akt and Bcl-2 inhibition induces cell-type specific modulation of apoptotic and autophagic signaling in castration resistant prostate cancer cell lines.
Avsar Abdik E; Abdik H; Turan D; Sahin F; Berger MR; Kaleagasioglu F
Mol Biol Rep; 2021 Dec; 48(12):7755-7765. PubMed ID: 34647221
[TBL] [Abstract][Full Text] [Related]
8. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
10. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
11. LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway.
Liu J; Fu XQ; Zhou W; Yu HG; Yu JP; Luo HS
World J Gastroenterol; 2011 Jan; 17(2):181-90. PubMed ID: 21245990
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status.
Buontempo F; Ersahin T; Missiroli S; Senturk S; Etro D; Ozturk M; Capitani S; Cetin-Atalay R; Neri ML
Invest New Drugs; 2011 Dec; 29(6):1303-13. PubMed ID: 20628892
[TBL] [Abstract][Full Text] [Related]
13. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
Yang CC; Lin HP; Chen CS; Yang YT; Tseng PH; Rangnekar VM; Chen CS
J Biol Chem; 2003 Jul; 278(28):25872-8. PubMed ID: 12738789
[TBL] [Abstract][Full Text] [Related]
14. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45.
Osaki M; Kase S; Adachi K; Takeda A; Hashimoto K; Ito H
J Cancer Res Clin Oncol; 2004 Jan; 130(1):8-14. PubMed ID: 14605879
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
17. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
18. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Krystal GW; Sulanke G; Litz J
Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
